Revvity, in collaboration with single-cell genomics company Honeycomb Biotechnologies, has announced the launch of a suite of new solutions and services that expand the frontiers of single-cell biology: the HIVE CLX Single-Cell RNAseq Solution, BeeNetPLUS analysis workflow.
The HIVE CLX Single-Cell RNAseq Solution offers higher density single-cell capture with integrated sample storage in an instrument-free workflow, making it easier for researchers to study rare and fragile cell types and better understand how the immune system fights allergens and pathogens, in addition to other applications. It is a significant upgrade to Honeycomb’s HIVE platform that was launched in collaboration with Revvity in 2021.
“The HIVE CLX solution is uniquely designed to enable clinical researchers to overcome challenges often encountered in single cell studies. User-friendly sample capture and storage expands both the scope and geographic reach of single cell research, especially in areas such as innate immunology and infectious disease,” said Jim Flanigon, CEO of Honeycomb. “Our colleagues at Revvity share our goal of bringing single-cell technology to a broader audience, so we’re excited to see our customers expand those boundaries with the HIVE CLX solution.”
Honeycomb’s HIVE CLX solution features 160,000 picowells within a single, high-density array that allows for as much as four times as many cells to be recovered per device as compared with the original HIVE scRNAseq solution. The premise is that more cells recovered translates to more transcripts processed, ultimately leading to more reliable, quality data that impacts health advances and biological insights across autoimmune research, oncology, neurology, developmental biology, transplant medicine and beyond.
By eliminating the need for specialised instrumentation, the HIVE CLX solution is well suited to support researchers working in remote or low-resource locations where sample storage and shipping requirements may be more complex. This includes studies involving emerging or evolving infectious diseases like HIV, malaria, tuberculosis and COVID-19, as well as distributed and longitudinal studies that involve multi-point sample collection.
“The ability to understand human health and disease at the single-cell level is notoriously challenging, but an incredibly important pursuit in biological and clinical research,” said Arvind Kothandaraman, General Manager of Multi-omics and Specialty Diagnostics at Revvity. “We are pleased that the HIVE CLX solution is helping scientists of all backgrounds and experience levels access single cell RNAseq technology.”
Further information on the HIVE CLX solution is available on Revvity's webpage, with additional protocols and technical information also available on the Honeycomb website.
